Here's Why Relmada Therapeutics Stock Popped Today
Shares of Relmada Therapeutics (NASDAQ: RLMD), a clinical-stage biopharmaceutical company, popped in response to a positive clinical trial readout with the company's lead candidate. Investors excited about REL-1017's positive human abuse potential trial results pushed the stock 37% higher at its peak this morning.
Relmada Therapeutics has settled down since its early morning pop. The stock was up by just 3.6% as of 11:25 a.m. EDT on Tuesday.
In the U.S. alone, around 20 million adults experience a case of major depressive disorder (MDD) annually, and available treatments often fail to restore patients to their preferred state. Relmada Therapeutics stock is jumping today because the study made it clear that REL-1017 is far less addictive than oxycodone.
Source Fool.com
